Tower Research Capital LLC (Trc) Nu Cana PLC Transaction History

Tower Research Capital LLC (Trc)

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	BUY	$0.76 - $1.69 $40 - $89	53 New	53 $0
Q1 2022 May 12, 2022	SELL	$0.74 - $3.27 $12,450 - $55,017	-16,825 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$2.02 - $2.9 $32,671 - $46,904	16,174 Added 2484.49%	16,825 $40,000
Q3 2021 Nov 15, 2021	SELL	$1.95 - $2.85 $335 - $490	-172 Reduced 20.9%	651 $2,000
Q2 2021 Aug 16, 2021	SELL	$2.7 - $5.04 $2,187 - $4,082	-810 Reduced 49.6%	823 $2,000
Q1 2021 May 17, 2021	BUY	$4.38 - $7.0 $7,152 - $11,431	1,633 New	1,633 $8,000
Q3 2020 Nov 16, 2020	SELL	$4.57 - $6.48 $1,462 - $2,073	-320 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$4.87 - $7.37 $1,558 - $2,358	320 New	320 $2,000
Q3 2019 Nov 05, 2019	SELL	$6.95 - $10.71 $21,489 - $33,115	-3,092 Closed	0 $0
Q2 2019 Aug 13, 2019	BUY	$9.74 - $17.45 $30,116 - $53,955	3,092 New	3,092 $32,000
Q2 2018 Aug 15, 2018	SELL	$19.0 - $29.84 $31,331 - $49,206	-1,649 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$10.04 - $28.25 $16,555 - $46,584	1,649 New	1,649 $31,000

3.33M

Ticker NCNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,196,000
Market Cap $69.9M
Description
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients ...

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.